RxDoctor Payments Data

Kelly Webster

Nurse Practitioner · Everett, WANPI 1336402718

Payments from drug & device makers

$3,631in general payments, 2019–2025

Across 70 payments — averaging $51.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$962
  • Cvrx, Inc.$560
  • Impulse Dynamics (USA) Inc.$368
  • Boehringer Ingelheim$272
  • Amgen$262
  • AstraZeneca$248
  • plus $960 from 12 others

What the payments were for

  • Food & beverage$3,60399%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,631 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$11,189
Medicare patients
75
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$78,965
JardianceEmpagliflozin70$63,396
EntrestoSacubitril/Valsartan39$47,082
XareltoRivaroxaban15$21,887
FarxigaDapagliflozin Propanediol22$16,534
Ezetimibe72$1,762
Metoprolol Succinate124$1,502
Prasugrel Hcl14$792
Atorvastatin Calcium110$715
ClopidogrelClopidogrel Bisulfate40$631
Rosuvastatin Calcium56$607
Carvedilol57$591
Spironolactone74$519
Valsartan19$482
Torsemide25$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$78,96570 claims
Boehringer IngelheimJardiance$272$63,39670 claims
NovartisEntresto$182$47,08239 claims
Johnson & JohnsonXarelto$17$21,88715 claims
AstraZenecaFarxiga$248$16,53422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →